Rhabdomyosarcoma

Children with rhabdomyosarcoma are different from general diseases of adults. There are two types of rhabdomyosarcoma: embryos and alveoli

Rhabdomyosarcoma of premature infants is most common in premature infants and is common in head and neck, bladder, vagina or prostate and testis.

Alveolar rhabdomyosarcoma occurs in all ages and often affects the large muscles of the arms, legs and fuselage.

Surgery - Remove as many tumors or as much tumor as possible for biopsy tumors (removing a small portion of the laboratory) and as much as possible

Chemotherapy ("chemotherapy") - Use strong drugs to kill cancer cells, prevent proliferation of cancer cells (divide), and make more cancer cells.

Radiation therapy - Use high energy X-rays or other kinds of radiation to prevent cancer cells from being killed or cancer cells from proliferating.

Internal radiation uses needles, seeds, wires or tubes (tubes) to irradiate the cancer directly or near the cancer

The survival rate depends on factors such as the size and position of the tumor, the amount of tumor that can be removed, and so on.

St. Jude is the only general cancer center designated by the National Cancer Institute.

St. Jude has created more cancer clinical trials than other American pediatric hospitals

The ratio of nurses to patients in St. Jude is unparalleled - liver disease and oncology are on average 1: 3, intensive care unit 1: 1

St. Jude Children's Research Hospital - The University of Washington University pediatric cancer genome project recently identified a drug that kills tumor cells grown in rhabdomyosarcoma in the laboratory. These medications may make chemotherapy more effective. This study also found that the two rhabdomyosarcomas had different genetic causes. This study provides insight as to why tumors recur after treatment. Scientists are conducting further research based on this research

After all treatments, researchers at St Jude are using a new combination of drugs to determine if they can extend the survival time of high-risk children

St. Jude staff uses new imaging techniques such as diffusion-weighted MRI to understand how tumors respond to treatment

St. Jude scientists are trying to find the most effective treatment with minimal treatment to treat children with low-risk rhabdomyosarcoma

Proton therapy may be necessary to treat St. Jude Rhabdomyosarcoma. St. Jude is currently constructing the only proton therapy center in the world specializing in the treatment of children. Proton beam therapy can provide high dose radiation directly to the tumor. This treatment can reduce normal tissue and reduce the side effects of traditional X-ray therapy. Because it is very accurate, proton therapy reduces the risk of child's serious side effects and the development of other cancers in later years.

The St. Jude Web site is provided for educational purposes only and is not intended to provide medical advice or professional services. The information provided through this website should not be used to diagnose or treat health problems or illness. It does not replace professional care. If you have health problems or are in doubt, you should consult your health care provider.

Treatment of rhabdomyosarcoma is a multidisciplinary treatment involving the use of surgery, chemotherapy, radiation therapy and possible immunotherapy. Surgery is usually the first step in combination therapy. Resectability depends on the site of the tumor and RMS often occurs at sites that do not allow complete surgical resection without significant morbidity and loss of function. Less than 20% of RMS tumors were completely excised and the margin was negative. Rhabdomyosarcoma is highly chemically sensitive, and approximately 80% of cases respond to chemotherapy. Indeed, all patients with rhabdomyosarcoma need multidrug combination chemotherapy. Survival rate treated only by surgery was less than 20% before use of chemotherapeutic agents and adjuvant including adjuvant adjuvant therapy. The modern survival rate of adjuvant therapy is about 60 - 70%

Undifferentiated (undifferentiated) rhabdomyosarcoma, also known as polymorphic rhabdomyosarcoma, is the last variant of RMS that is recognized in most classification systems. Undifferentiated rhabdomyosarcoma is defined as the presence of undifferentiated cells with large leafy chromatin nuclei and multipolar mitotic maps. These tumors show high heterogeneity and poor differentiation. Undifferentiated cells can be diffuse or focal, and diffuse changes are associated with poor prognosis. It happens most frequently in adults, rarely in children, and is often seen in limbs. Due to the lack of identifiable separation during this type of cancer, clinicians often classify sarcomas that have not been diagnosed as undifferentiated RMS with little or no distinctive features. It is the most aggressive RMS and usually requires intensive care